Cargando…

Chronic Exposure to GLP-1 Increases GLP-1 Synthesis and Release in a Pancreatic Alpha Cell Line (α-TC1): Evidence of a Direct Effect of GLP-1 on Pancreatic Alpha Cells

AIMS/HYPOTHESIS: Incretin therapies, which are used to treat diabetic patients, cause a chronic supra-physiological increase in GLP-1 circulating levels. It is still unclear how the resulting high hormone concentrations may affect pancreatic alpha cells. The present study was designed to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piro, Salvatore, Mascali, Loriana G., Urbano, Francesca, Filippello, Agnese, Malaguarnera, Roberta, Calanna, Salvatore, Rabuazzo, Agata M., Purrello, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938588/ https://www.ncbi.nlm.nih.gov/pubmed/24587221 http://dx.doi.org/10.1371/journal.pone.0090093

Ejemplares similares

Chronic Exposure to Palmitate Impairs Insulin Signaling in an Intestinal L-cell Line: A Possible Shift from GLP-1 to Glucagon Production
por: Filippello, Agnese, et al.
Publicado: (2018)

Direct Effects of D-Chiro-Inositol on Insulin Signaling and Glucagon Secretion of Pancreatic Alpha Cells
por: Filippello, Agnese, et al.
Publicado: (2020)

Pancreatic alpha cells in diabetic rats express active GLP-1 receptor: Endosomal co-localization of GLP-1/GLP-1R complex functioning through intra-islet paracrine mechanism
por: Nakashima, Koji, et al.
Publicado: (2018)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes
por: Heidarzadeh, Sara, et al.
Publicado: (2013)

Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012)

miR-296-3p, miR-298-5p and their downstream networks are causally involved in the higher resistance of mammalian pancreatic α cells to cytokine-induced apoptosis as compared to β cells
por: Barbagallo, Davide, et al.
Publicado: (2013)

Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists
por: Umapathysivam, Mahesh M, et al.
Publicado: (2023)

GLP‐1 suppresses glucagon secretion in human pancreatic alpha‐cells by inhibition of P/Q‐type Ca(2+) channels
por: Ramracheya, Reshma, et al.
Publicado: (2018)

Metabolic regulation of GLP-1 and PC1/3 in pancreatic α-cell line
por: Sancho, Veronica, et al.
Publicado: (2017)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Effect of GLP-1/GLP-1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis
por: Yang, Li, et al.
Publicado: (2021)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

Glucolipotoxicity and GLP-1 secretion
por: Hong, Jung-Hee, et al.
Publicado: (2021)

GLP-1 and Intestinal Diseases
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

GLP-1R–Targeting Magnetic Nanoparticles for Pancreatic Islet Imaging
por: Wang, Ping, et al.
Publicado: (2014)

1 h Postload Glycemia Is Associated with Low Endogenous Secretory Receptor for Advanced Glycation End Product Levels and Early Markers of Cardiovascular Disease
por: Di Pino, Antonino, et al.
Publicado: (2019)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

Counselling Patients for GLP-1 Analogue Therapy: Comparing GLP-1 Analogue with Insulin Counselling
por: Kalra, Sanjay, et al.
Publicado: (2012)

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
por: Li, Junfeng, et al.
Publicado: (2017)

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
por: Meurot, C., et al.
Publicado: (2022)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
por: Matikainen, Niina, et al.
Publicado: (2016)

Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat β-Cells. Direct Effect of Oxidative Stress
por: Urbano, Francesca, et al.
Publicado: (2017)

Pancreatic GLP-1r binding potential is reduced in insulin-resistant pigs
por: Malbert, Charles-Henri, et al.
Publicado: (2020)

Author Correction: Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat β-Cells. Direct Effect of Oxidative Stress
por: Urbano, Francesca, et al.
Publicado: (2020)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Ultrastructural Study on Colocalization of Glucagon-Like Peptide (GLP)-1 with GLP-2 in Chicken Intestinal L-Cells
por: NISHIMURA, Kei, et al.
Publicado: (2013)

Diabetes-Associated Common Genetic Variation and Its Association With GLP-1 Concentrations and Response to Exogenous GLP-1
por: Smushkin, Galina, et al.
Publicado: (2012)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

A toolkit of tagged glp-1 alleles reveals strong glp-1 expression in the germline, embryo, and spermatheca
por: Sorensen, Erika B, et al.
Publicado: (2020)

Cardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?
por: Liu, Yangyang, et al.
Publicado: (2020)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto's thyroiditis
por: Jin, Yue, et al.
Publicado: (2015)

GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
por: Abdalqadir, Nyan, et al.
Publicado: (2022)

Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells
por: Manchanda, Yusman, et al.
Publicado: (2023)

Microbial regulation of GLP-1 and L-cell biology
por: Greiner, Thomas U., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lrmfecmld7cphv6ra0m2q1mh27